Research graph
References from Patients’ access to drugs with rebates in Switzerland – Empirical analysis and policy implications for drug pricing in Europe. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries
10.1007/s40258-016-0300-z · 2017 · External reference
Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis
10.1016/s1470-2045(20)30139-x · 2020 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
The difficulty of comparing drug prices between countries
10.1016/s1470-2045(16)00176-5 · 2016 · External reference
Discounts and rebates granted to public payers for medicines in European countries
2012 · External reference
Unresolved reference
External reference
International reference pricing for prescription drugs in the United States: administrative limitations and collateral effects
2020 · External reference
Unresolved reference
External reference
Payers’ experiences with confidential pharmaceutical price discounts: a survey of public and statutory health systems in North America, Europe, and Australasia
10.1016/j.healthpol.2017.02.002 · 2017 · External reference
Unresolved reference
2010 · External reference
Differential pricing for pharmaceuticals: reconciling access, R&D and patents
10.1023/a:1025384819575 · 2003 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study
10.1136/bmj.m3434 · 2020 · External reference
Comparative assessment of clinical benefit using the ESMO-magnitude of clinical benefit scale version 1.1 and the ASCO value framework net health benefit score
10.1200/jco.18.00729 · 2019 · External reference
ESMO-magnitude of clinical benefit scale version 1.1
10.1093/annonc/mdx310 · 2017 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Does external reference pricing deliver what it promises? Evidence on its impact at national level
10.1007/s10198-019-01116-4 · 2020 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Price, value, and the cost of cancer drugs
10.1016/s1470-2045(15)00564-1 · 2016 · External reference
